SIRT1 and neoplasm: SIRT1 was identified as a direct target for miR-22, and miR-22 might act as a tumor suppressor in RCC and blocks RCC growth and metastasis by direct targeting of SIRT1, indicating a potential new therapeutic effect in RCC therapy45.